Venatorx pharmaceuticals: antibiotic for AMR and biothreat pathogens

Active Definitive Contract Awarded Last action

Contract number
75A50122C00080
Awardee
Awarding agency
Obligated
$72,141,707

Award facts

Opportunity
Contract value 23% obligated
  • $72,141,707.00 Current, with exercised options
  • $318,625,321.00 Potential, with all options
Completion date 41% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Malvern, PA 19355, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00006 · The purpose of this modification is to report information via fpds for contracts being aligned with the presidential cost savings initiative. $0
Other Administrative Action P00005 · The purpose of this modification is to update articles i.1 federal acquisition regulation (far) (48 CFR chapter 1) clauses, 52.204-14 services contract… $0
Other Administrative Action P00004 · The purpose of this modification is to update articles g.1 contracting officer (CO), g.4. Key personnel, and g.5. Contract financial report. $0
Other Administrative Action P00003 · The purpose of this modification is to update article g.12. Indirect cost rate $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 · The purpose of this modification is to update article g.4. Key personnel $0
Original award $72,141,707

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response awarded a $318.6 million definitive contract to Venatorx Pharmaceuticals Inc. for late-stage development and regulatory approval of an antibiotic to treat infections caused by Yersinia pestis, Francisella tularensis, and Burkholderia pseudomallei on September 27, 2022.

The contract is priced as cost plus fixed fee with a ceiling value of $318,625,321 and an ultimate completion date of September 22, 2032. Place of performance is Malvern, PA. The originating pre-solicitation, posted in December 2021, sought proposals to support antibiotic development through Project BioShield for delivery to the Strategic National Stockpile or vendor-managed inventory. The anticipated period of performance was up to 120 months. Relevant NAICS codes include 541711 for research and development in biotechnology and 339112 for surgical and medical instrument manufacturing. The procurement was conducted in full and open competition with no set-aside applied.

Quick answers

Who was awarded contract 75A50122C00080?

75A50122C00080 was awarded to Venatorx Pharmaceuticals Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 27, 2022.

How much is contract 75A50122C00080 worth?

The government has obligated $72,141,707 on 75A50122C00080. Its potential value, with all options, is $318,625,321.

Was contract 75A50122C00080 competed?

The extent of competition for 75A50122C00080 was full and open competition. The government received 3 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login